

AiDA Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

<https://marketpublishers.com/r/A44E41676C2BEN.html>

Date: August 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: A44E41676C2BEN

Abstracts

AiDA Pharmaceuticals, Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between AiDA Pharmaceuticals, Inc. and its competitors. This provides our Clients with a clear understanding of AiDA Pharmaceuticals, Inc. position in the Industry.

The report contains detailed information about AiDA Pharmaceuticals, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for AiDA Pharmaceuticals, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The AiDA Pharmaceuticals, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and

company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes AiDA Pharmaceuticals, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of AiDA Pharmaceuticals, Inc. business.

About AiDA Pharmaceuticals, Inc.

AiDA Pharmaceuticals, Inc., through its subsidiaries, engages in the development, production, and distribution of antibiotics, cardiovascular, and anti cancer drugs. The company offers its products in the form of powder for injection, liquid for intravenous injection, capsule, tablet, and ointment in the People's Republic of China.

Products

The company's products include Etimicin Sulfate Injection Powder; Etimicin Sulfate Injection liquid; and Etimicin Sulfate for transfusion.

Etimicin Sulfate is an antibiotic developed in the PRC which is used for the treatment of various inflammations, including respiratory infection, such as acute bronchitis, acute onset of chronic bronchitis, and pulmonary infections; kidney and urinogenital infection, such as acute pyelonephritis or acute onset of chronic cystitis; soft skin tissue infection; and trauma and operations preventive uses.

Products under development

The company's products under development include:

Apoptotic Factor (rh-Apo2l): Rh-Apo2l is in phase II trial as a cancer therapeutic. The company acquired two patents for this product.

Vasostatin –Apo2L: This product is a protein that is tested as a cancer drug. It integrates the function of extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of rh-Apo2l which induces the apoptosis of cancer cells.

Prodigiosin to Treat Pancreatic Cancer: Prodigiosin, a naturally occurring red pigment, is in pre-clinical trials for the treatment of pancreatic cancer. The company develops a method to utilize the biochemical properties of Prodigiosin to create a non-invasive treatment for pancreatic cancer.

Anti-CD86 Monoclonal Antibody to Treat Immunity Diseases: Certain immunity diseases activate T-cells, causing them to unnecessarily attack healthy tissue. The company develops the Anti-CD86 Monoclonal Antibody to inhibit T-cells from harming healthy tissue. It is under preclinical research.

Anti-CTLA-4 Monoclonal Antibody to Inhibit Tumor Growth: In the case of certain cancers, tumors over-express self-proteins, essentially hiding the tumor from the immune system. The company is in the development stage of an Anti-CTLA-4 Monoclonal Antibody, which relieves the inhibition of T-cells allowing them to identify the over-expressed proteins and in turn naturally attacking cancer cells without harming healthy tissues. It is under preclinical research.

Subsidiaries

The company's subsidiaries include Earjoy Group Limited; Hangzhou Aida Pharmaceutical Co., Ltd; Hangzhou Boda Medical Research and Development Co., Ltd.; Hainan Aike Pharmaceutical Co., Ltd.; Changzhou Fangyuan Pharmaceutical Co., Ltd.; and Shanghai Qiaer Bio-technology Co., Ltd.

Suppliers

The company's suppliers include Changzhou Fangyuan Pharmaceutical Co., Ltd. and Shanhe Pharmaceuticals Co., Ltd.

History

AIDA Pharmaceuticals, Inc. was founded in 1999.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. AIDA PHARMACEUTICALS, INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. AIDA PHARMACEUTICALS, INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. AIDA PHARMACEUTICALS, INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. AIDA PHARMACEUTICALS, INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
 - 4.1.1. Income Statement
 - 4.1.2. Balance Sheet
 - 4.1.3. Cash Flow
- 4.2. Financial Ratios
 - 4.2.1. Profitability
 - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. AIDA PHARMACEUTICALS, INC. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. AiDA Pharmaceuticals, Inc. Direct Competitors
- 5.2. Comparison of AiDA Pharmaceuticals, Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of AiDA Pharmaceuticals, Inc. and Direct Competitors Stock Charts
- 5.4. AiDA Pharmaceuticals, Inc. Industry Analysis
 - 5.4.1. Industry Snapshot
 - 5.4.2. AiDA Pharmaceuticals, Inc. Industry Position Analysis

6. AIDA PHARMACEUTICALS, INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. AIDA PHARMACEUTICALS, INC. EXPERTS REVIEW¹

- 7.1. Experts Consensus
- 7.2. Experts Revisions

8. AIDA PHARMACEUTICALS, INC. ENHANCED SWOT ANALYSIS²

9. CHINA PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

10. AIDA PHARMACEUTICALS, INC. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix

10.2. External Factor Evaluation Matrix

10.3. Internal External Matrix

11. AIDA PHARMACEUTICALS, INC. PORTER FIVE FORCES ANALYSIS²

12. AIDA PHARMACEUTICALS, INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

AiDA Pharmaceuticals, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit

Profit Margin Chart

Operating Margin Chart

Return on Equity (ROE) Chart

Return on Assets (ROA) Chart

Debt to Equity Chart

Current Ratio Chart

AiDA Pharmaceuticals, Inc. 1-year Stock Charts

AiDA Pharmaceuticals, Inc. 5-year Stock Charts

AiDA Pharmaceuticals, Inc. vs. Main Indexes 1-year Stock Chart

AiDA Pharmaceuticals, Inc. vs. Direct Competitors 1-year Stock Charts

AiDA Pharmaceuticals, Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

AiDA Pharmaceuticals, Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
AiDA Pharmaceuticals, Inc. Key Executives
AiDA Pharmaceuticals, Inc. Major Shareholders
AiDA Pharmaceuticals, Inc. History
AiDA Pharmaceuticals, Inc. Products
Revenues by Segment
Revenues by Region
AiDA Pharmaceuticals, Inc. Offices and Representations
AiDA Pharmaceuticals, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
AiDA Pharmaceuticals, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
AiDA Pharmaceuticals, Inc. Capital Market Snapshot
AiDA Pharmaceuticals, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Industry Statistics

AiDA Pharmaceuticals, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
AiDA Pharmaceuticals, Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors

integrated into one suggestive model.

Porter Five Forces Analysis

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity

Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?

I would like to order

Product name: AiDA Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: <https://marketpublishers.com/r/A44E41676C2BEN.html>

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A44E41676C2BEN.html>